XOMA (NASDAQ:XOMA) Cut to Sell at StockNews.com

StockNews.com downgraded shares of XOMA (NASDAQ:XOMA) from a hold rating to a sell rating in a report published on Tuesday.

Separately, HC Wainwright reduced their price objective on XOMA from $123.00 to $104.00 and set a “buy” rating for the company in a research note on Monday, February 3rd.

XOMA Trading Down 1.0 %

NASDAQ XOMA opened at $22.70 on Tuesday. The firm’s 50 day moving average price is $26.04 and its two-hundred day moving average price is $27.92. The stock has a market cap of $267.47 million, a price-to-earnings ratio of -6.52 and a beta of 0.90. XOMA has a twelve month low of $21.27 and a twelve month high of $35.00. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52.

Insider Transactions at XOMA

In other XOMA news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the company’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $26.10, for a total value of $13,069,366.20. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 7.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On XOMA

Several large investors have recently made changes to their positions in the company. Woodline Partners LP increased its position in XOMA by 63.9% during the fourth quarter. Woodline Partners LP now owns 156,266 shares of the biotechnology company’s stock worth $4,107,000 after buying an additional 60,927 shares during the last quarter. Nuveen Asset Management LLC increased its holdings in shares of XOMA by 3.8% during the 4th quarter. Nuveen Asset Management LLC now owns 14,363 shares of the biotechnology company’s stock valued at $377,000 after acquiring an additional 527 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of XOMA by 34.7% during the 4th quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company’s stock valued at $205,000 after acquiring an additional 2,009 shares during the last quarter. Northern Trust Corp raised its stake in shares of XOMA by 1.5% in the 4th quarter. Northern Trust Corp now owns 91,181 shares of the biotechnology company’s stock valued at $2,396,000 after acquiring an additional 1,340 shares in the last quarter. Finally, Eversept Partners LP grew its holdings in XOMA by 1.2% during the fourth quarter. Eversept Partners LP now owns 95,417 shares of the biotechnology company’s stock valued at $2,508,000 after purchasing an additional 1,128 shares during the last quarter. Institutional investors own 95.92% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.